Search research articles
Contact Us
Filters
Showing results (401-410 of 487) with videos related to
Page
of 49
Sort By:
Diagnosis (Berlin, Germany)
|
August 1, 2024
Bridging the divide: addressing discrepancies between clinical guidelines, policy guidelines, and biomarker utilization
Denis Horgan, Paul Hofman, Reinhard Buttner, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 10, 2025
A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies
Vincent Ribrag, Lara Iglesias, Filippo De Braud, et al.
NPJ Precision Oncology
|
April 18, 2023
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies
Omar Alhalabi, Roman Groisberg, Ralph Zinner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2023
Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes
Ryan A Denu, Richard K Yang, Alexander J Lazar, et al.
Oncotarget
|
September 3, 2016
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
Haeseong Park, Ignacio Garrido-Laguna, Aung Naing, et al.
JCO Precision Oncology
|
September 14, 2020
Targeting <i>ERBB2</i> (<i>HER2</i>) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications
Ecaterina E Ileana Dumbrava, Kavitha Balaji, Kanwal Raghav, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 24, 2018
BRAF Inhibition in <i>BRAF</i><sup>V600</sup>-Mutant Gliomas: Results From the VE-BASKET Study
Thomas Kaley, Mehdi Touat, Vivek Subbiah, et al.
Oncotarget
|
May 28, 2015
Clinical next generation sequencing to identify actionable aberrations in a phase I program
Genevieve M Boland, Sarina A Piha-Paul, Vivek Subbiah, et al.
Oncotarget
|
April 19, 2014
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
Denis L Fontes Jardim, Debora de Melo Gagliato, Gerald S Falchook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 2, 2022
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)
Hani Babiker, Erkut Borazanci, Vivek Subbiah, et al.
Page
of 49
Search research articles
Search
Showing results (401-410 of 487) with videos related to
Sort By:
Page
of 49
Diagnosis (Berlin, Germany)
|
August 1, 2024
Bridging the divide: addressing discrepancies between clinical guidelines, policy guidelines, and biomarker utilization
Denis Horgan, Paul Hofman, Reinhard Buttner, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 10, 2025
A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies
Vincent Ribrag, Lara Iglesias, Filippo De Braud, et al.
NPJ Precision Oncology
|
April 18, 2023
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies
Omar Alhalabi, Roman Groisberg, Ralph Zinner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2023
Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes
Ryan A Denu, Richard K Yang, Alexander J Lazar, et al.
Oncotarget
|
September 3, 2016
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
Haeseong Park, Ignacio Garrido-Laguna, Aung Naing, et al.
JCO Precision Oncology
|
September 14, 2020
Targeting <i>ERBB2</i> (<i>HER2</i>) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications
Ecaterina E Ileana Dumbrava, Kavitha Balaji, Kanwal Raghav, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 24, 2018
BRAF Inhibition in <i>BRAF</i><sup>V600</sup>-Mutant Gliomas: Results From the VE-BASKET Study
Thomas Kaley, Mehdi Touat, Vivek Subbiah, et al.
Oncotarget
|
May 28, 2015
Clinical next generation sequencing to identify actionable aberrations in a phase I program
Genevieve M Boland, Sarina A Piha-Paul, Vivek Subbiah, et al.
Oncotarget
|
April 19, 2014
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
Denis L Fontes Jardim, Debora de Melo Gagliato, Gerald S Falchook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 2, 2022
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)
Hani Babiker, Erkut Borazanci, Vivek Subbiah, et al.
Page
of 49